Tag:
Cellestis
Latest Headlines
Latest Headlines
Qiagen amends offer for Cellestis, provides update on Ipsogen
Qiagen has amended its original proposal to acquire Australia's Cellestis, increasing its per-share offer price to A$3.80 ($4.06) from the original offer price of A$3.55 ($3.79). The amended...
